Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients.
As part of the initial research project, Tempus will use its Tempus O platform to collect and structure clinical data from the cancer center’s electronic health record. Tempus also will provide next generation sequencing and analysis for a subset of patients in order to identify actionable gene alterations.